Q-omics provides the consensus-scored THNSL1 profile across patient tissues and cancer cell-line models. THNSL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THNSL1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, THNSL1 protein abundance shows 22,616 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where THNSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THNSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THNSL1 survival associations across molecular data types. THNSL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THNSL1 RNA expression–survival associations across cancer types. High THNSL1 expression shows unfavorable associations in BLCA and CESC, but favorable associations in KIRC, LUSC, MESO and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THNSL1 RNA expression.
This table summarizes THNSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THNSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THNSL1 shows lower tumor expression in THCA and KICH and higher tumor expression in LUAD, COAD, LUSC and STAD. The THCA box plot shows higher THNSL1 RNA expression in normal versus tumor tissue (log2 FC = −1.358, t-test p < 0.001).
This table shows molecular features associated with THNSL1 in patient tissues and cancer cell lines. In patient samples, THNSL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, THNSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
